Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients With Decompensated Cirrhosis

被引:28
|
作者
Mort, Joseph F. [1 ]
Davis, Jessica P. E. [2 ]
Mahoro, Giselle [3 ]
Stotts, Matthew J. [2 ]
Intagliata, Nicolas M. [2 ]
Northup, Patrick G. [2 ]
机构
[1] Univ Virginia, Charlottesville, VA USA
[2] Univ Virginia, Sch Med, Ctr Coagulat Liver Dis, Div Gastroenterol & Hepatol,Dept Med, Charlottesville, VA 22908 USA
[3] Univ Virginia, Dept Med, Charlottesville, VA USA
关键词
INR; Real-World; Blood Clot; Drug; PORTAL-VEIN THROMBOSIS; ATRIAL-FIBRILLATION; COAGULOPATHY; DEFINITION; EFFICACY; DISEASE; SAFETY; RISK;
D O I
10.1016/j.cgh.2020.08.007
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Studies of the effects of direct oral anticoagulants (DOACs) in patients with cirrhosis have been limited by their small sample size, inclusion of patients with well-compensated cirrhosis, short follow-up times, inadequate validation of cirrhosis diagnoses, and non-standard definitions of bleeding. We aimed to systematically determine the characteristics, indications, and outcomes of patients with cirrhosis of all severity classes who received DOACs. METHODS: We performed a retrospective study of 138 patients with confirmed cirrhosis (93 with Child-Turcotte-Pugh scores of B or C) at a single center who started DOAC therapy (58,984 person-days; median, 181 days per patient) from September 2011 through April 2019. We collected data on clinical characteristics, indications for DOAC use, and outcomes. Standardized and validated definitions for bleeding complications were used. RESULTS: Twenty-nine patients (21%) stopped therapy due to a diagnosis of or perceived bleeding. The most common bleeding events were non-variceal upper and lower intestinal bleeding. No pretreatment laboratory parameters were associated with bleeding while patients received treatment, including platelet count (P = .50), international normalized ratio (P = .34), creatinine (P = .27), and model for end-stage liver disease score (P = .22). Frequency of bleeding events related to DOAC did not differ significantly among patients of different Child-Turcotte-Pugh classes (P = .81), DOAC indications (P = .60), or DOAC dosages (P = .10). Higher proportions of patients with hepatocellular carcinoma (P = .01) had major bleeding while receiving. CONCLUSIONS: Patients with decompensated cirrhosis have significant bleeding and rates of discontinuation of DOACs when they take them long term. Pretreatment laboratory parameters, DOAC dose, and Child-Turcotte-Pugh class were not associated with bleeding; hepatocellular carcinoma was associated with major bleeding.
引用
收藏
页码:1436 / 1442
页数:7
相关论文
共 50 条
  • [31] Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants
    Tchen, Stephanie
    Ryba, Nicole
    Patel, Vishal
    Cavanaugh, Joseph
    Sullivan, Jesse B.
    [J]. ANNALS OF PHARMACOTHERAPY, 2020, 54 (12) : 1175 - 1184
  • [32] Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
    Baker, Christine L.
    Dhamane, Amol D.
    Mardekian, Jack
    Dina, Oluwaseyi
    Russ, Cristina
    Rosenblatt, Lisa
    Lingohr-Smith, Melissa
    Menges, Brandy
    Lin, Jay
    Nadkarni, Anagha
    [J]. ADVANCES IN THERAPY, 2019, 36 (01) : 162 - 174
  • [33] Prevention and Treatment of Bleeding with Direct Oral Anticoagulants
    R. Monroe Crawley
    Rachel L. Anderson
    [J]. Drugs, 2020, 80 : 1293 - 1308
  • [34] Act quickly to manage bleeding in patients taking direct oral anticoagulants
    Fenton, Caroline
    Lee, Arnold
    [J]. DRUGS & THERAPY PERSPECTIVES, 2021, 37 (05) : 199 - 205
  • [35] Prevention and Treatment of Bleeding with Direct Oral Anticoagulants
    Crawley, R. Monroe
    Anderson, Rachel L.
    [J]. DRUGS, 2020, 80 (13) : 1293 - 1308
  • [36] Act quickly to manage bleeding in patients taking direct oral anticoagulants
    Caroline Fenton
    Arnold Lee
    [J]. Drugs & Therapy Perspectives, 2021, 37 : 199 - 205
  • [37] Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
    Kim, Gwang-Un
    Lee, Sinwon
    Choe, Jaewon
    Hwang, Sung Wook
    Park, Sang Hyoung
    Ye, Byong Duk
    Byeon, Jeong-Sik
    Myung, Seung-Jae
    Yang, Suk-Kyun
    Yang, Dong-Hoon
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [38] Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
    Gwang-Un Kim
    Sinwon Lee
    Jaewon Choe
    Sung Wook Hwang
    Sang Hyoung Park
    Byong Duk Ye
    Jeong-Sik Byeon
    Seung-Jae Myung
    Suk-Kyun Yang
    Dong-Hoon Yang
    [J]. Scientific Reports, 11
  • [39] ASSOCIATION BETWEEN GENETIC POLYMORPHISMS AND BLEEDING IN PATIENTS ON DIRECT ORAL ANTICOAGULANTS
    Song, T. -J.
    Chang, Y.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (03) : 402 - 402
  • [40] Risk of Hemorrhoidal Bleeding in Patients Treated with Direct Oral Anticoagulants (DOACs)
    Petruzziello, Carmine
    Saviano, Angela
    Brigida, Mattia
    Migneco, Alessio
    Manetti, Luca Luigi
    Candelli, Marcello
    Ojetti, Veronica
    [J]. GASTROINTESTINAL DISORDERS, 2024, 6 (03): : 634 - 643